ID: ALA4475591

Max Phase: Preclinical

Molecular Formula: C21H27N5O

Molecular Weight: 365.48

Molecule Type: Unknown

Representations

Canonical SMILES:  Cc1cccc(Nc2nc(NC3CCCCC3N)cc3c2C(=O)NCC3)c1

Standard InChI:  InChI=1S/C21H27N5O/c1-13-5-4-6-15(11-13)24-20-19-14(9-10-23-21(19)27)12-18(26-20)25-17-8-3-2-7-16(17)22/h4-6,11-12,16-17H,2-3,7-10,22H2,1H3,(H,23,27)(H2,24,25,26)

Standard InChI Key:  MCKWNSLSBBIMNO-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 365.48

Molecular Weight (Monoisotopic): 365.2216

AlogP: 3.10

#Rotatable Bonds: 4

Polar Surface Area: 92.07

Molecular Species: BASE

HBA: 5

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 9.92

CX LogP: 4.40

CX LogD: 2.00

Aromatic Rings: 2

Heavy Atoms: 27

QED Weighted: 0.67

Np Likeness Score: -0.34

References

1. Taniguchi T, Inagaki H, Baba D, Yasumatsu I, Toyota A, Kaneta Y, Kiga M, Iimura S, Odagiri T, Shibata Y, Ueda K, Seo M, Shimizu H, Imaoka T, Nakayama K..  (2019)  Discovery of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors with Antitumor Activity.,  10  (5): [PMID:31097992] [10.1021/acsmedchemlett.8b00631]

Source

Source(1):

• Scientific Literature